{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:11:26Z","timestamp":1760933486561,"version":"build-2065373602"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physical Medicine and Rehabilitation Clinics of North America"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.pmr.2012.09.003","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T04:30:24Z","timestamp":1350448224000},"page":"801-820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Pharmacologic Management in Selected Neuromuscular Diseases"],"prefix":"10.1016","volume":"23","author":[{"given":"Andrew J.","family":"Skalsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjorn","family":"Oskarsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay J.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Richman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pmr.2012.09.003_bib1","first-page":"304","article-title":"Over idioptische hypertrophie van het hart","volume":"76","author":"Pompe","year":"1932","journal-title":"Ned Tidschr Geneeskd"},{"key":"10.1016\/j.pmr.2012.09.003_bib2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","article-title":"Pompe disease in infants and children","volume":"144","author":"Kishnani","year":"2004","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.pmr.2012.09.003_bib3","first-page":"344","article-title":"Biochemical aspects of glycogen deposition disease","volume":"3","author":"Cori","year":"1957","journal-title":"Mod Probl Paediatr"},{"key":"10.1016\/j.pmr.2012.09.003_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"Alpha-glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem J"},{"key":"10.1016\/j.pmr.2012.09.003_bib5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1042\/bj0600604","article-title":"Tissue fractionation studies","volume":"60","author":"de Duve","year":"1955","journal-title":"Biochem J"},{"key":"10.1016\/j.pmr.2012.09.003_bib6","first-page":"382","article-title":"Acid maltase deficiency: comparison of infantile, childhood, and adult types","volume":"20","author":"Engel","year":"1970","journal-title":"Neurology"},{"key":"10.1016\/j.pmr.2012.09.003_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/mus.21393","article-title":"Diagnostic criteria for late-onset (childhood and adult) Pompe disease","volume":"40","author":"American Association of Neuromuscular & Electrodiagnostic Medicine","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pmr.2012.09.003_bib8","first-page":"45","article-title":"Role of autophagy in the pathogenesis of Pompe disease","volume":"26","author":"Raben","year":"2007","journal-title":"Acta Myol"},{"key":"10.1016\/j.pmr.2012.09.003_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1651-2227.2006.tb02395.x","article-title":"Lysosomal dysfunction, cellular pathology and clinical symptoms: basic principles","volume":"95","author":"Reuser","year":"2006","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pmr.2012.09.003_bib10","unstructured":"Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency. Scriver's MMBID website. Available at: http:\/\/www.ommbid.com\/\/OMMBID\/the_online_metabolic_and_molecular_bases_of_inherited_disease\/b\/abstract\/part16\/ch135. Accessed September 9, 2012."},{"key":"10.1016\/j.pmr.2012.09.003_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.pmr.2012.09.003_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A\u00a0retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.pmr.2012.09.003_bib13","first-page":"184","article-title":"Enzyme replacement in Pompe disease: an attempt with purified human acid alpha-glucosidase","volume":"9","author":"de Barsy","year":"1973","journal-title":"Birth Defects Orig Artic Ser"},{"key":"10.1016\/j.pmr.2012.09.003_bib14","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.pmr.2012.09.003_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1469-1809.1984.tb00833.x","article-title":"Confirmation of the regional localization of the genes for human acid alpha-glucosidase (GAA) and adenosine deaminase (ADA) by somatic cell hybridization","volume":"48","author":"Honig","year":"1984","journal-title":"Ann Hum Genet"},{"year":"2010","series-title":"MYOZYME [package insert]","key":"10.1016\/j.pmr.2012.09.003_bib16"},{"key":"10.1016\/j.pmr.2012.09.003_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.pmr.2012.09.003_bib18","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A\u00a0randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"year":"2010","series-title":"LUMIZYME [package insert]","key":"10.1016\/j.pmr.2012.09.003_bib19"},{"issue":"3","key":"10.1016\/j.pmr.2012.09.003_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","article-title":"Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease","volume":"45","author":"Cupler","year":"2012","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.pmr.2012.09.003_bib21","first-page":"497","article-title":"Clinical guidelines for late-onset Pompe disease","volume":"54","author":"Barba-Romero","year":"2012","journal-title":"Rev Neurol"},{"key":"10.1016\/j.pmr.2012.09.003_bib22","unstructured":"Genzyme. Lumizyme ACE program. Available at: http:\/\/www.lumizyme.com\/ace\/. Accessed July 13, 2012."},{"key":"10.1016\/j.pmr.2012.09.003_bib23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0959-4388(96)80103-6","article-title":"Therapeutic horizons for amyotrophic lateral sclerosis","volume":"6","author":"Rothstein","year":"1996","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.pmr.2012.09.003_bib24","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.2174\/092986710791163939","article-title":"Riluzole, neuroprotection and amyotrophic lateral sclerosis","volume":"17","author":"Cheah","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pmr.2012.09.003_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.50.1.62","article-title":"Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis","volume":"50","author":"Gurney","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.pmr.2012.09.003_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A\u00a0controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pmr.2012.09.003_bib27","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.pmr.2012.09.003_bib28","first-page":"609","article-title":"A\u00a0study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis","volume":"249","author":"Bensimon","year":"2002","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.pmr.2012.09.003_bib29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/14660820410021249","article-title":"Changes in the management of ALS since the publication of the AAN ALS practice parameter 1999","volume":"5","author":"Bradley","year":"2004","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"3","key":"10.1016\/j.pmr.2012.09.003_bib30","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pmr.2012.09.003_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature03180","article-title":"Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression","volume":"433","author":"Rothstein","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.pmr.2012.09.003_bib32","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/nm.2579","article-title":"The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis","volume":"17","author":"Cudkowicz","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.pmr.2012.09.003_bib33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0404.1989.tb03851.x","article-title":"Pathologic laughter and crying in ALS: a search for their origin","volume":"80","author":"Gallagher","year":"1989","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.pmr.2012.09.003_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852900026614","article-title":"Defining and diagnosing involuntary emotional expression disorder","volume":"11","author":"Cummings","year":"2006","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pmr.2012.09.003_bib35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ana.22093","article-title":"Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect","volume":"68","author":"Pioro","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pmr.2012.09.003_bib36","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM198506063122303","article-title":"Treatment of pathologic laughing and weeping with amitriptyline","volume":"312","author":"Schiffer","year":"1985","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pmr.2012.09.003_bib37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archneur.64.4.530","article-title":"Continuum of frontal lobe impairment in amyotrophic lateral sclerosis","volume":"64","author":"Murphy","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pmr.2012.09.003_bib38","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/mus.21245","article-title":"Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study","volume":"39","author":"Rabkin","year":"2009","journal-title":"Muscle Nerve"},{"issue":"Supp 3","key":"10.1016\/j.pmr.2012.09.003_bib39","first-page":"A199","article-title":"The spectrum of patient symptoms in ALS and symptom management","volume":"56","author":"Heiman-Patterson","year":"2001","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.pmr.2012.09.003_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005044.pub2","article-title":"Quinine for muscle cramps","author":"El-Tawil","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pmr.2012.09.003_bib41","unstructured":"FDA Drug Safety Communication: New risk management plan and patient Medication Guide for Qualaquin (quinine sulfate). Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm218202.htm. Accessed September 9, 2012."},{"key":"10.1016\/j.pmr.2012.09.003_bib42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","article-title":"Acquired immune and inflammatory myopathies: pathologic classification","volume":"23","author":"Pestronk","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.pmr.2012.09.003_bib43","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pmr.2012.09.003_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pmr.2012.09.003_bib45","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1210\/jc.2009-2161","article-title":"Muscle fiber conduction slowing and decreased levels of circulating muscle proteins after short-term dexamethasone administration in healthy subjects","volume":"95","author":"Minetto","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pmr.2012.09.003_bib46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial","volume":"20","author":"Van de Vlekkert","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.pmr.2012.09.003_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/art.1780240107","article-title":"Prednisone and azathioprine for polymyositis: long-term followup","volume":"24","author":"Bunch","year":"1981","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pmr.2012.09.003_bib48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":"Azathioprine with prednisone for polymyositis. A controlled, clinical trial","volume":"92","author":"Bunch","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pmr.2012.09.003_bib49","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/rheumatology\/kel336","article-title":"Mycophenolate mofetil treatment in resistant myositis","volume":"46","author":"Pisoni","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pmr.2012.09.003_bib50","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A\u00a0controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pmr.2012.09.003_bib51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pmr.2012.09.003_bib52","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/BOR.0b013e32834b53cc","article-title":"Inclusion body myositis","volume":"23","author":"Greenberg","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.pmr.2012.09.003_bib53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1750-3639.2009.00290.x","article-title":"Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation","volume":"19","author":"Askanas","year":"2009","journal-title":"Brain Pathol"},{"key":"10.1016\/j.pmr.2012.09.003_bib54","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.pmr.2012.09.003_bib55","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.pmr.2012.09.003_bib56","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mus.20440","article-title":"Molecular architecture of the neuromuscular junction","volume":"33","author":"Hughes","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pmr.2012.09.003_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00605.x","article-title":"Immunology of disorders of neuromuscular transmission","volume":"183","author":"Vincent","year":"2006","journal-title":"Acta Neurol Scand, Suppl"},{"issue":"2","key":"10.1016\/j.pmr.2012.09.003_bib58","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0035-3787(04)70888-7","article-title":"Lambert-Eaton myasthenic syndrome","volume":"160","author":"Newsom-Davis","year":"2004","journal-title":"Rev Neurol (Paris)"},{"issue":"12","key":"10.1016\/j.pmr.2012.09.003_bib59","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Richman","year":"2003","journal-title":"Neurology"},{"issue":"8008","key":"10.1016\/j.pmr.2012.09.003_bib60","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(77)92639-3","article-title":"Plasma exchange in myasthenia gravis","volume":"1","author":"Pinching","year":"1977","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pmr.2012.09.003_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002277.pub3","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.pmr.2012.09.003_bib62","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.pmr.2012.09.003_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pmr.2012.09.003_bib64","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A\u00a0randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pmr.2012.09.003_bib65","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1586\/eci.10.57","article-title":"3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome","volume":"6","author":"Wirtz","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"10.1016\/j.pmr.2012.09.003_bib66","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.40.10.1552","article-title":"Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma","volume":"40","author":"Chalk","year":"1990","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pmr.2012.09.003_bib67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.nmd.2011.10.009","article-title":"Current status of the congenital myasthenic syndromes","volume":"22","author":"Engel","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.pmr.2012.09.003_bib68","first-page":"98","article-title":"Diagnostics and therapy of muscle channelopathies\u2013Guidelines of the Ulm Muscle Centre","volume":"27","author":"Lehmann-Horn","year":"2008","journal-title":"Acta Myol"},{"issue":"6","key":"10.1016\/j.pmr.2012.09.003_bib69","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/WNF.0b013e3181ae5546","article-title":"Fluoxetine blocks myotonic runs and reverts abnormal surface electromyogram pattern in patients with myotonic dystrophy type 1","volume":"32","author":"Chisari","year":"2009","journal-title":"Clin Neuropharmacol"},{"issue":"18","key":"10.1016\/j.pmr.2012.09.003_bib70","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.pmr.2012.09.003_bib71","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0404.1992.tb05103.x","article-title":"Treatment of myotonia with antiarrhythmic drugs","volume":"86","author":"Kwieci\u0144ski","year":"1992","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"10.1016\/j.pmr.2012.09.003_bib72","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2169\/internalmedicine.44.1027","article-title":"New classification and treatment for myotonic disorders","volume":"44","author":"Kurihara","year":"2005","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.pmr.2012.09.003_bib73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.pmr.2012.09.003_bib74","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1113\/expphysiol.2010.053025","article-title":"Progress in therapy for Duchenne muscular dystrophy","volume":"96","author":"Fairclough","year":"2011","journal-title":"Exp Physiol"},{"issue":"8","key":"10.1016\/j.pmr.2012.09.003_bib75","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrd3459","article-title":"Targeting RNA to treat neuromuscular disease","volume":"10","author":"Muntoni","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"9791","key":"10.1016\/j.pmr.2012.09.003_bib76","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.pmr.2012.09.003_bib77","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne's muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.pmr.2012.09.003_bib78","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1089\/hum.2011.127","article-title":"Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy","volume":"23","author":"Verhaart","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"R1","key":"10.1016\/j.pmr.2012.09.003_bib79","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1093\/hmg\/ddr105","article-title":"Therapeutic approaches to muscular dystrophy","volume":"20","author":"Goyenvalle","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.pmr.2012.09.003_bib80","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/humu.20428","article-title":"Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy","volume":"28","author":"B\u00e9roud","year":"2007","journal-title":"Hum Mutat"},{"issue":"5","key":"10.1016\/j.pmr.2012.09.003_bib81","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/mt.2011.59","article-title":"Current status of pharmaceutical and genetic therapeutic approaches to treat DMD","volume":"19","author":"Pichavant","year":"2011","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.pmr.2012.09.003_bib82","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/0883073810371129","article-title":"Read-through strategies for suppression of nonsense mutations in Duchenne\/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124)","volume":"25","author":"Finkel","year":"2010","journal-title":"J\u00a0Child Neurol"},{"issue":"12","key":"10.1016\/j.pmr.2012.09.003_bib83","doi-asserted-by":"crossref","first-page":"e29376","DOI":"10.1371\/journal.pone.0029376","article-title":"Translational regulation of utrophin by miRNAs","volume":"6","author":"Basu","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pmr.2012.09.003_bib84","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/mus.21743","article-title":"Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy","volume":"42","author":"Morine","year":"2010","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.pmr.2012.09.003_bib85","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A\u00a0phase I\/II trial of MYO-029 in adult subjects with muscular dystrophy","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pmr.2012.09.003_bib86","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1755-8794-4-36","article-title":"Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy","volume":"4","author":"Kemaladewi","year":"2011","journal-title":"BMC Med Genomics"},{"issue":"6","key":"10.1016\/j.pmr.2012.09.003_bib87","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.nmd.2011.02.016","article-title":"Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial","volume":"21","author":"Buyse","year":"2011","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.pmr.2012.09.003_bib88","article-title":"Drug treatment for spinal muscular atrophy type I","author":"Wadman","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.pmr.2012.09.003_bib89","article-title":"Drug treatment for spinal muscular atrophy types II and III","author":"Wadman","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.pmr.2012.09.003_bib90","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1399-0004.2009.01200.x","article-title":"Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling","volume":"76","author":"Rudnik-Sch\u00f6neborn","year":"2009","journal-title":"Clin Genet"},{"issue":"8","key":"10.1016\/j.pmr.2012.09.003_bib91","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJMcibr1114629","article-title":"Sense in antisense therapy for spinal muscular atrophy","volume":"366","author":"MacKenzie","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.pmr.2012.09.003_bib92","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/hmg\/ddp510","article-title":"Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy","volume":"19","author":"Butchbach","year":"2010","journal-title":"Hum Mol Genet"}],"container-title":["Physical Medicine and Rehabilitation Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047965112001003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047965112001003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T03:35:52Z","timestamp":1760931352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1047965112001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1047965112001003"],"URL":"https:\/\/doi.org\/10.1016\/j.pmr.2012.09.003","relation":{},"ISSN":["1047-9651"],"issn-type":[{"type":"print","value":"1047-9651"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Pharmacologic Management in Selected Neuromuscular Diseases","name":"articletitle","label":"Article Title"},{"value":"Physical Medicine and Rehabilitation Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmr.2012.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}